Loading patent…
AssigneesThe Regents of the University of California, Charite-Universitatsmedizin Berlin, Mt. Sinai Hospital
InventorsMichael Demetriou, Alexander Brandt, Paul Friedmann, James Dennis
Estimating the term…
The invention provides the art with a powerful diagnostic method of distinguishing relapse-remitting MS subjects from progressive MS subjects, based on the measurement of serum concentrations of N-acetylglucosamine (GlcNAc,), for the first time enabling rapid diagnosis of the progressive form of MS. GlcNAc serum concentration can also be used to assess neurodegenerative status and MS progression in subjects suffering from MS or other neurological conditions. The methods of the invention also allow for the identification of new therapeutics for MS and other neurological conditions and also enables the personalized efficacy assessment of a potential therapy for an MS subject.
A method of diagnosing the MS subtype of an MS subject, comprising the steps of
A method of assessing neurodegenerative severity in a subject having a neurodegenerative condition, comprising the steps of
-18. (canceled)
A method of treating an MS patient, wherein the patient is receiving an ongoing treatment for the relapse-remitting form of MS, comprising the steps of
Dependencies are inferred from the claim text.